However, the suitability of these antigens as CAR-T targets still needs to be proven in the future, as they are currently in clinical trials, while CD22 has already been shown to be a highly specific CAR-T target with great capacity and efficiency in clinical trials, especially in hematological malignancies. This evidence concerns the gene CD22 and hematologic disorder.